CVS Pharmacy, Inc. v. Lavin

951 F.3d 50
CourtCourt of Appeals for the First Circuit
DecidedFebruary 28, 2020
Docket19-1638P
StatusPublished
Cited by16 cases

This text of 951 F.3d 50 (CVS Pharmacy, Inc. v. Lavin) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
CVS Pharmacy, Inc. v. Lavin, 951 F.3d 50 (1st Cir. 2020).

Opinion

United States Court of Appeals For the First Circuit

No. 19-1638

CVS PHARMACY, INC.,

Plaintiff, Appellee,

v.

JOHN LAVIN,

Defendant, Appellant.

APPEAL FROM THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF RHODE ISLAND

[Hon. John J. McConnell, Jr., U.S. District Judge]

Before

Lynch, Selya, and Lipez, Circuit Judges.

John J. Cotter, with whom Jennifer J. Nagle and K&L Gates LLP were on brief, for appellant. Michael L. Rosen, with whom Richard G. Baldwin, Allison L. Anderson, and Foley Hoag LLP were on brief, for appellee.

February 28, 2020 LIPEZ, Circuit Judge. After working for nearly three

decades at plaintiff-appellee CVS Pharmacy, Inc., defendant-

appellant John Lavin accepted a new position at PillPack LLC, a

direct competitor of CVS. But Lavin never actually started that

job. After obtaining information about Lavin's new role, CVS sued

Lavin, seeking to enforce a covenant not to compete (the "covenant"

or the "Agreement") included in a Restrictive Covenant Agreement

("RCA") that Lavin signed in 2017. Finding that Lavin's new

position would violate the covenant and concluding that the

covenant was reasonable, the district court entered a preliminary

injunction enjoining Lavin from working at PillPack for eighteen

months, the duration specified in the covenant. In this

interlocutory appeal, Lavin argues that the covenant is not

reasonable and that the preliminary injunction, therefore, should

not have been granted. Although our reasoning differs somewhat

from that of the district court, we affirm the entry of a

preliminary injunction enforcing the covenant not to compete.

- 2 - I.

A. Factual Background1

1. CVS Caremark's Business

CVS operates CVS Caremark, one of the country's largest

pharmacy benefit managers ("PBMs"). PBMs sell prescription-

management services to entities providing prescription-drug

coverage to their members. These entities -- known as payers --

include employers, insurance companies, and unions. PBMs

negotiate on behalf of payers with pharmacies to secure

reimbursement rates for prescription drugs. They also establish

pharmacy networks for payers, premised on each payer's individual

needs and preferences; furnish an array of administrative services

(such as claims adjudication and eligibility determinations); and

procure bulk discounts and rebates directly from pharmaceutical

manufacturers. For its part, CVS Caremark offers its own mail-

order pharmacy services to certain payers as clients.

CVS operates other healthcare-related subsidiaries in

addition to CVS Caremark, including a sprawling chain of retail

pharmacies. CVS has erected a firewall between CVS Caremark and

its retail pharmacy subsidiary. This firewall not only prevents

1 "[W]e credit the undisputed facts presented below and adopt the district court's findings as to controverted matters to the extent they are supported by the record and not clearly erroneous." United Elec., Radio & Mach. Workers of Am. v. 163 Pleasant St. Corp., 960 F.2d 1080, 1083 (1st Cir. 1992).

- 3 - CVS Caremark's employees from accessing the prices that CVS's

retail pharmacies negotiate with other PBMs but also prevents

employees of CVS's retail pharmacies from accessing the prices

that CVS Caremark negotiates with other retail pharmacies.

2. Lavin's Employment at CVS

After his almost three decades at CVS Caremark and its

predecessor, Lavin became Senior Vice President for Provider

Network Services in 2010. In this role, he oversaw a team of

approximately 250 people and was responsible for negotiating

pricing contracts with retail pharmacies, auditing pharmacies, and

setting up pharmacy networks for payers. He also participated in

regular underwriting calls for the contracts that CVS Caremark

negotiated with its payer clients. In light of these duties, he

became intimately familiar with the prices and terms of CVS

Caremark's deals with both retail pharmacies and payers.

Lavin was also involved in certain strategic initiatives

undertaken by CVS Caremark. For instance, he assisted with the

company's strategy for contracting with mail-in retail pharmacies

("MIRs"), which fill prescriptions by mail. This project included

developing strategies about how best to differentiate CVS

Caremark's mail-based services from those offered by MIRs. He

helped formulate CVS Caremark's strategy for the upcoming

contracting cycle and create novel pharmacy reimbursement and

pricing models. Each year, he attended several executive committee

- 4 - meetings that covered an array of topics ranging from revenue and

pricing to major client accounts and regulatory impacts.

3. Noncompetition Agreement

At four points during his tenure as a senior vice

president at CVS Caremark -- in 2011, 2012, 2014, and 2017 -- CVS

required Lavin to sign an RCA. Each RCA contained noncompetition,

nonsolicitation, and nondisclosure covenants. Each time Lavin

signed an RCA, he was awarded CVS stock.

The 2017 RCA, executed in exchange for a stock award

worth $157,500, is the centerpiece of this appeal. The covenant

not to compete contained therein bars Lavin, for eighteen months

after the termination of his employment, from "directly or

indirectly . . . engag[ing] in Competition" anywhere in the United

States that CVS operates. The covenant in the 2017 RCA defines

"Competition" as:

[P]roviding services to a Competitor of the Corporation [CVS] . . . that: (i) are the same or similar in function or purpose to the services I [Lavin] provided to the Corporation at any time during the last two years of my employment by the Corporation; or (ii) will likely result in the disclosure of Confidential Information to a Competitor or the use of Confidential Information on behalf of a Competitor.

"Competitor" is defined, in turn, as:

[A]ny person, corporation or other entity that competes with one or more of the business offerings of the Corporation[.] . . . [T]he Corporation's business offerings include:

- 5 - (i) pharmacy benefits management ("PBM") . . .; (ii) retail, which includes the sale of prescription drugs, over-the-counter medications, [and other products and services sold by CVS's retail pharmacies] ("Retail"); (iii) retail health clinics ("MinuteClinic"); (iv) the provision of [various products and services] to long-term care facilities, other healthcare service providers and recipients of services from such facilities ("Long-Term Care"); (v) the provision of prescription infusion drugs and related services ("Infusion"); and (vi) any other business in which [the] Corporation is engaged or imminently will be engaged.

. . . .

The Parties acknowledge that . . . an entity will be considered a Competitor if it provides products or services competitive with the products and services provided by the Corporation within the last two years of my employment.

I agree to this enterprise-wide definition of non-competition which may prevent me from providing services to any of the Corporation's PBM, Retail, MinuteClinic, Long-Term Care and Infusion Competitors or any combination thereof . . . .

This definition of "Competition" and the eighteen-month

noncompetition period appear in all four of the RCAs that Lavin

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
951 F.3d 50, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cvs-pharmacy-inc-v-lavin-ca1-2020.